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Abstract
Background: Lysophospholipids regulate the morphology and growth of neurons, neural cell
lines, and neural progenitors. A stable human neural progenitor cell line is not currently available
in which to study the role of lysophospholipids in human neural development. We recently
established a stable, adherent human embryonic stem cell-derived neuroepithelial (hES-NEP) cell
line which recapitulates morphological and phenotypic features of neural progenitor cells isolated
from fetal tissue. The goal of this study was to determine if hES-NEP cells express functional
lysophospholipid receptors, and if activation of these receptors mediates cellular responses critical
for neural development.
Results: Our results demonstrate that Lysophosphatidic Acid (LPA) and Sphingosine-1-phosphate
(S1P) receptors are functionally expressed in hES-NEP cells and are coupled to multiple cellular
signaling pathways. We have shown that transcript levels for S1P1 receptor increased significantly
in the transition from embryonic stem cell to hES-NEP. hES-NEP cells express LPA and S1P
receptors coupled to Gi/o G-proteins that inhibit adenylyl cyclase and to Gq-like phospholipase C
activity. LPA and S1P also induce p44/42 ERK MAP kinase phosphorylation in these cells and
stimulate cell proliferation via Gi/o coupled receptors in an Epidermal Growth Factor Receptor
(EGFR)- and ERK-dependent pathway. In contrast, LPA and S1P stimulate transient cell rounding
and aggregation that is independent of EGFR and ERK, but dependent on the Rho effector p160
ROCK.
Conclusion: Thus, lysophospholipids regulate neural progenitor growth and morphology through
distinct mechanisms. These findings establish human ES cell-derived NEP cells as a model system
for studying the role of lysophospholipids in neural progenitors.
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Background
We have previously generated a stable neuroepithelial
(NEP) cell line derived from human embryonic stem
(hES) cells (hES-NEP) that is grown under adherent con-
ditions, is self-renewing, and stably maintains capacity for
neuronal or glial differentiation. These hES-NEP cells
recapitulate morphological and phenotypic features of
neural progenitor cells isolated from fetal tissue [1]. Such
a cell line has potential both as a source for specific neu-
ronal lineages to be used in hES cell neural therapy and as
an in vitro model system in which to study human NEP
cell function and its regulation by signaling mediators
such as lysophospholipids. The lysophospholipid signal-
ing mediators Lysophosphatidic Acid (LPA) and Sphingo-
sine 1-phosphate (S1P) are critical regulators of neural
development, modulating neural growth, morphogene-
sis, and differentiation.
Lysophospholipid signaling has been implicated in medi-
ating diverse physiological and pathological responses,
including cancer progression, wound healing, angiogen-
esis, cardiovascular development, and, more recently,
neural development (Reviews: [2-5]). There is strong evi-
dence that both LPA and S1P are critical in early neural
development, as mouse embryos that lack enzymes for
S1P or LPA synthesis exhibit severe neural tube defects.
Specifically, mice with genetic deletion of Sphingosine
kinases required for production of S1P developed cranial
neural tube defects as a result of increased apoptosis,
decreased mitosis and subsequent thinning of the neu-
roepithelial progenitor cell layer [6]. These data suggest
that S1P mediates anti-apoptotic and pro-growth signal-
ing in normal neuroepithelial development. Similarly,
genetic deletion of Autotaxin, the enzyme responsible for
production of LPA in the brain, yields embryonically
lethal mice with neural tube defects. In these embryos, the
neural tube fails to close completely and is kinked [7].
Further, embryos lacking LPA exhibited asymmetric neu-
ral headfold, reflecting large effusions with high levels of
apoptotic cells [8]. These studies demonstrate critical and
distinct roles of S1P and LPA in early neural development.
LPA and S1P receptors are expressed in neural progeni-
tors, neurons, and oligodendrocytes in the developing
and adult brain, and both LPA and S1P are generated by
neurons [9-11]. The biological consequences of lysophos-
pholipid signaling in the nervous system are incompletely
defined, but evidence for several roles in neural progeni-
tors is emerging. As discussed above, there are clear roles
for S1P and LPA in early neural tube development. Fur-
ther, LPA appears to regulate cortical neurogenesis by pro-
moting morphological changes, survival, and
differentiation [12,13]. Finally, S1P activity is implicated
in mediating migration of neural progenitor cells toward
sites of spinal injury [10]. Thus, LPA and S1P regulate crit-
ical responses in neural progenitor cells that may be
exploited to manipulate these cells in traditional pharma-
cological or cell-based therapeutics.
LPA and S1P bind and activate cell surface G-protein cou-
pled receptors (GPCRs) to regulate cell proliferation, dif-
ferentiation, and morphological changes, all of which
may contribute to their roles in regulating neural progen-
itor cell function. There are at least five distinct LPA recep-
tors (LPA1-LPA5) and five S1P receptors (S1P1-S1P5)
[14]. LPA and S1P receptors couple to multiple G-protein
pathways to regulate ion channel activity, adenylyl cyclase
mediated cyclic AMP (cAMP) production, phospholipase
C (PLC) mediated inositol phosphate production and cal-
cium release, activation of the small GTPase Rho, and
transactivation of receptor tyrosine kinase receptors
(Review: [15]).
Regulation of cell growth and morphology are common
effects of lysophospholipids. LPA and S1P have potent
proliferative effects in multiple neural cell lines [16-18].
For example, LPA induces proliferation in neurospheres
isolated from rat embryonic cortex [19], and application
of S1P to neural progenitor cells from embryonic rat hip-
pocampus has been shown to stimulate Gi/o pathways
which activate Mitogen-Activated Protein (MAP) kinases
and DNA synthesis [20]. The latter observation is consist-
ent with the mechanism for lysophospholipid stimulated
proliferation in many cancer cells, in which LPA receptors
transactivate the epidermal growth factor receptor (EGFR)
pathway, resulting in MAP kinase activation and subse-
quent proliferation [16-18].
LPA and S1P also stimulate specific cytoskeletal rearrange-
ments, likely contributing to their roles in axonal path-
finding and migration. Neural cell lines such as NIE-115
cells and PC12 cells undergo rapid and transient neurite
retraction in response to LPA and S1P [21,22]. LPA
induces neurite retraction within minutes, and neurons
re-extend neurites after LPA is removed; thus, the retrac-
tion is dynamic and may fine tune neurite growth [23,24].
Similar neurite retraction and growth cone collapse occur
in response to LPA in differentiating cortical neurons [23].
Morphological changes also occur in neural progenitor
cells, which lack distinct neurites. Both LPA and S1P cause
transient aggregation of rat hippocampal neural progeni-
tor cells [20], and LPA stimulates cluster contraction,
lamellipodia retraction and migration toward the center
of the cluster in mouse cortical neuroblasts [11]. LPA
stimulates cell rounding of cortical neural progenitors,
important in cortical neurogenesis [11]. The mechanisms
for these effects is incompletely understood, but in most
cases LPA and S1P induced morphological changes can be
partially or completely blocked by pretreatment withBMC Neuroscience 2008, 9:118 http://www.biomedcentral.com/1471-2202/9/118
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inhibitors of the small GTPase Rho or its primary effector
in neurons, p160 Rho kinase (ROCK) [23,24].
The goal of the current study was to define functional lys-
ophospholipid receptor signaling pathways in hES-NEP
cells. We have determined that functional LPA and S1P
receptors are expressed in hES-NEPs and regulate second
messenger pathways, MAP kinase-dependent cell prolifer-
ation, and Rho-dependent morphology changes. These
results contribute to the molecular characterization of
hES-NEP cells, and establish for the first time a human,
multipotent, renewable model cell system in which to
define the role of LPA and S1P in neural progenitor cell
function.
Results
LPA and S1P receptor mRNA transcript expression 
changes during the transition from ES cells to hES-NEP 
cells
Expression of transcript encoding all five LPA receptors
has been reported in hES cells and in hES cell-derived neu-
rospheres [25], and three S1P receptors (S1P1-3) have
also been detected in hES cells [26]. As described, the hES-
NEP cell line used in this study was derived from the hES
cell line, WA09. We performed quantitative RT-PCR to
determine expression of transcript of LPA and S1P recep-
tor subtypes in hES-NEP cells, and to determine if receptor
expression changed in the transition from embryonic
stem cell line to neural epithelial cell line. WA09 ES cells
had detectable levels of transcript for all five LPA receptor
genes and all five S1P receptor genes; however, in the hES-
NEP population LPA3 and S1P4 were not expressed at
detectable levels after 40 amplifications. Because the RT-
PCR primer pairs used have been shown to have equiva-
lent amplification efficiency (100% +/- 10%) at the
annealing temperatures used, the relative expression of
LPA and S1P receptors can be directly compared within
hES-NEP cell RNA. The ΔCT value for each receptor tran-
script was determined by normalizing with CT values for
the endogenous 18s ribosomal RNA. As shown in Figure
1A, LPA5 receptor transcript expression was significantly
lower than LPA1, 2, and 4. Similarly, S1P 1, 2, and 3 tran-
scripts were expressed at significantly higher levels in hES-
NEP cells than S1P5. We further determined the fold
change in transcript expression of LPA1, 2, 4, and 5 and
S1P 1, 2, 3, and 5 in hES-NEP cells relative to their expres-
sion in the parent ES cell line WA09. LPA1 receptor tran-
script expression was increased approximately ten fold
while LPA2 expression was decreased approximately five
fold in cumulative data representing three experiments,
but these changes did not meet criteria for statistical sig-
nificance. Expression of LPA4 and 5 mRNA transcripts
were relatively unchanged between the two populations.
S1P1 receptor transcript was dramatically upregulated
approximately forty fold in hES-NEP cells relative to the
parent ES cell line (Figure 1B), while significant changes
were not observed in expression of S1P 2, 3, and 5 tran-
script.
NEP cells express functional LPA and S1P receptors
To evaluate expression of GPCRs for LPA and S1P as well
as major neurotransmitter classes in hES-NEP cells, we
screened agonists of adrenergic, dopamine, muscarinic
acetylcholine, LPA, and S1P receptors for activity in assays
measuring second messenger production. First, we
assessed activity of these compounds in inositol phos-
phate assays that measure PLC activity. Cells were stimu-
lated with each of the following drugs at a concentration
of 10 μM for 30 minutes: clonidine (α2 adrenergic recep-
tor agonist), epinephrine (general adrenergic receptor
agonist), quinpirole (D2-like dopamine receptor agonist),
bromocriptine (D2-like dopamine receptor agonist), car-
bachol (general muscarinic acetylcholine receptor ago-
nist), and S1P (general S1P receptor agonist); 18:1
(Oleoyl) LPA (general LPA receptor agonist) was tested at
a concentration of 1 μM due to loss of activity at higher
concentrations. At these concentrations, only LPA and
S1P stimulated a significant increase in inositol phos-
phate accumulation compared to vehicle treatment in
hES-NEP cells (Figure 2A). We then generated LPA and
S1P dose-response curves in these cells. The EC50 for inosi-
tol phosphate accumulation stimulated by either LPA or
S1P is approximately 25 nM (Figure 2B, C). Pre-incuba-
tion with 100 ng/mL of the Gi/o selective inhibitor Pertus-
sis toxin (Ptx) for 18 hours did not inhibit S1P stimulated
IP accumulation, indicating that this effect is not medi-
ated by Gi/o G-proteins, while Ptx consistently inhibited
30–40% of the LPA stimulated IP accumulation (T, Fig-
ure 2B, C).
We next determined if hES-NEP cells express functional
adrenergic, dopamine, or lysophospholipid receptors
coupled to Gs-like increases in cAMP production. hES-
NEP cells were treated with the same panel of agonist
compounds (although quinpirole, bromocriptine, and
carbachol do not activate any known Gs coupled recep-
tors), and none produced a significant increase in cAMP,
suggesting there are not functional Gs coupled LPA, S1P,
adrenergic, or dopaminergic receptors expressed in hES-
NEP cells (data not shown). Finally, the receptor agonists
were added to cells following activation of adenylyl
cyclase with forskolin to determine if they could decrease
cAMP production via Gi/o mediated inhibition of adenylyl
cyclase. Adrenergic and dopaminergic receptor agonists
had no effect on forskolin-stimulated cAMP levels, and
carbachol produced a modest inhibition of cAMP produc-
tion. In contrast, both LPA and S1P significantly inhibited
forskolin-stimulated cAMP accumulation by approxi-
mately 50% and 40%, respectively, at 10 μM doses (Figure
3A). Dose response curves demonstrated that LPA inhib-BMC Neuroscience 2008, 9:118 http://www.biomedcentral.com/1471-2202/9/118
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ited forskolin-stimulated cAMP accumulation with an
EC50 of approximately 10 nM (Figure 3B), while S1P had
an EC50 of approximately 5 nM (Figure 3C). The activity of
both LPA and S1P was completely inhibited by pre-incu-
bation of cells with 100 ng/mL Ptx (T, Figure 3B, C), con-
firming that this effect is mediated by Gi/o G-proteins.
LPA and S1P promote growth of hES-NEP cells via Ptx-
sensitive G-proteins, EGF receptors, and MAP kinases
To examine the effects of S1P and LPA on cellular growth,
we determined the ability of LPA and S1P to stimulate
growth of cultured hES-NEP cells over a 36 hour period by
determining increases in cell number (Figure 4). hES-NEP
LPA and S1P receptor subtype transcript expression in hES-NEP cells Figure 1
LPA and S1P receptor subtype transcript expression in hES-NEP cells. A Semi-quantitative RT-PCR from hNP cells 
revealed the relative expression of receptor mRNA. Higher expression is equivalent to a smaller delta CT value (CT value of 
RNA - CT value of 18s). Statistical significance was measured using a one-way analysis of variance (ANOVA) and Tukey's post-
hoc comparisons were used to test the significance between all pairwise comparisons (p < .05). Data is represented as the 
mean ΔCT +/- S.E.M. (CT value of gene - CT value of 18 s) of 3 biological replicates. * in A demonstrates a significant difference 
(greater expression) than S1P5, * in B demonstrates a significant difference (greater expression) than LPA5. N.D. indicates that 
the average CT was >35 indicated that the mRNA signal was not detectable. B. Total RNA was isolated from WA09 hES cells 
and hES-NEP cells, and relative expression of each LPA and S1P receptor transcript was determined using quantitative RT-
PCR. Results are reported as fold change in RNA transcript in hES-NEP cells relative to ES cells (details of data analysis in 
Methods). Data represents three compiled independent experiments and was subjected to ANOVA, tukey post-hoc analysis. 
Error bars represent standard error; *: p < 0.0001.BMC Neuroscience 2008, 9:118 http://www.biomedcentral.com/1471-2202/9/118
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hES-NEP cells express functional LPA and S1P receptors coupled to PLC Figure 2
hES-NEP cells express functional LPA and S1P receptors coupled to PLC. (A) hES-NEP cells were treated with each 
of the indicated drugs at 10 μM, except for LPA which was assessed at 1 μM, for 30 minutes and assayed for IP levels as 
described in Methods. Results are reported as percent of basal inositol phosphate accumulation (CPM) with counts for drug 
treated wells divided by data from vehicle treated wells. (B) hES-NEP cells were treated with various concentrations of LPA in 
the presence (star) or absence (square) of Ptx for 30' and assayed for IP production. (C) hES-NEP cells were treated with var-
ious concentrations of S1P in the presence (star) or absence (square) of Ptx for 30' and assayed for IP production. Data are 
consistent with three independent experiments.BMC Neuroscience 2008, 9:118 http://www.biomedcentral.com/1471-2202/9/118
Page 6 of 18
(page number not for citation purposes)
cells were plated in 24-well plates and grown to 50% con-
fluence. Cells were then grown for 36 hours with vehicle,
1 nM, 10 nM, or 100 nM LPA or S1P added to the normal
growth media. Cells were not subjected to starve condi-
tions, and therefore continued to grow at a normal basal
rate in the absence of added lysophospholipid. Cells
under basal growth conditions showed a 60% increase in
cell number (increased to 170,000 cells/well at 36 hours,
from 108,000 cells/well at time zero). Addition of lyso-
phospholipid resulted in a dose-dependent increase in
cell growth from 1 nM to 100 nM LPA (Figure 4A) and
from 1 nM to 100 nM S1P (Figure 4B), with S1P showing
an apparent higher potency. Cells treated with 100 nM
LPA showed a 120% increase in cell number after 36
hours (235,000 cells at 36 hours), and cells treated with
100 nM of S1P showed a similar 130% increase in cell
number (252,000 cells at 36 hours), as compared to the
60% increase in control cells. The basal growth rate was
approximately linear over the 36 hour experiment (4B),
and this rate was increased significantly by addition of
100 nM of either LPA (4B) or S1P (4D) as early as 12
hours. The rate of growth of LPA and S1P treated cells
slowed at later time points as these cells approached con-
fluency.
MAP kinases such as p44 and p42 Extracellular signal Reg-
ulated Kinases (ERKs) are known to play an important
role in neural progenitor cell proliferation [27-29], and
both LPA and S1P activate the MAP kinase pathway in
multiple systems [20,30-37]. Further, LPA has been
shown to activate MAP kinase pathways through a Gi/o-
dependent EGF receptor transactivation mechanism [16-
18]. To determine which of these pathways is functional
in lysophospholipid stimulated growth of hES-NEP cells,
the effects of pretreatment with specific pharmacological
inhibitors of pathway intermediates were determined: the
Gi/o selective inhibitor Ptx (100 ng/mL), the EGF receptor
inhibitor AG1478 (2.5 μM), the MAP kinase/ERK Kinase
(MEK) inhibitor U0126 (10 μM), the direct ERK inhibitor
FR180204 (10 μM), and the p160ROCK inhibitor Y27632
(10  μM). Cells were counted after pre-treatment with
inhibitor and again after an 18 hour incubation with LPA
(Figure 5B) or S1P (Figure 5D). Both LPA and S1P signif-
icantly induced increased cell growth over vehicle at this
time point. Pre-treatment with Ptx, AG1478, U0126, and
FR180204 completely inhibited both basal cell growth
and LPA and S1P stimulated growth; however, the
p160ROCK inhibitor Y27632 did not significantly affect
basal growth or growth stimulated by either LPA or S1P.
Further, pre-treatment with the inhibitors did not increase
cell staining with Trypan Blue, indicating that these com-
pounds were not cytotoxic at the concentrations used
(data not shown). These results suggest that LPA and S1P
promote growth of hES-NEP cells through a mechanism
dependent on Ptx-sensitive Gi/o G-proteins, EGF receptor,
hES-NEP cells express functional Gi/o-coupled LPA and S1P  receptors Figure 3
hES-NEP cells express functional Gi/o-coupled LPA 
and S1P receptors. (A) hES-NEP cells were treated with 
50 μM forskolin and 10 μM of each of the indicated drugs for 
20', then assayed for cAMP levels as described in Materials 
and Methods. hES-NEP cells were treated with 50 μM for-
skolin and various concentrations of LPA (B) or S1P (C) for 
20' in the presence (star) or absence (square) of Ptx. Data 
are consistent with three independent experiments.BMC Neuroscience 2008, 9:118 http://www.biomedcentral.com/1471-2202/9/118
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LPA and S1P promote growth of hES-NEP cells Figure 4
LPA and S1P promote growth of hES-NEP cells. (A, C) hES-NEP cells were plated in 24-well plates and grown to 50% 
confluence, and the treated with vehicle or 1–100 nM LPA (A) or S1P (C) for 36 hours and then counted. (B, D) Cells were 
incubated with vehicle or 100 nM LPA (B) or 100 nM S1P (D) and cell growth was determined at 12, 24, and 36 hours. Viable 
cells were counted and reported as the number of new cells/well. The number of cells at time zero (108,000) has been sub-
tracted from all data shown. Data are representative of two independent experiments analyzed using an unpaired 2-tailed t-
test. *: p < 0.05; **: p < 0.01.BMC Neuroscience 2008, 9:118 http://www.biomedcentral.com/1471-2202/9/118
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LPA and S1P effects of hES-NEP cell growth are mediated by Ptx sensitive G-proteins, EGF receptors, and ERK Map kinases Figure 5
LPA and S1P effects of hES-NEP cell growth are mediated by Ptx sensitive G-proteins, EGF receptors, and 
ERK Map kinases. hES-NEP cells were pre-treated with 100 ng/mL Ptx, 2.5 μM AG1478, 10 μM U0126, 10 μM FR180204, 10 
μM Y27632 or no treatment (NT) overnight and then treated with 100 nM LPA (A), 100 nM S1P (B) or vehicle. Cells were 
counted after treatment with inhibitors (time zero) and again after incubation with LPA or S1P. Results are reported as the 
number of new cells per well after LPA or S1P treatment; cell numbers at time zero have been subtracted. Data are represent-
ative of two independent experiments analyzed using an unpaired 2-tailed t-test. Comparisons were made between the LPA 
stimulated fold increase over basal growth in each condition. *: p < 0.05; **: p < 0.01.BMC Neuroscience 2008, 9:118 http://www.biomedcentral.com/1471-2202/9/118
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MEK, and ERK, but independent of the Rho-associated
kinase p160ROCK.
The data above implicate MAP kinase activation in the
ability of LPA and S1P to stimulate cell growth. Thus, we
directly tested the ability of LPA and S1P to stimulate
phosphorylation of the MAP kinase proteins p44/42 ERK.
We performed Western blotting on cellular lysates after
treating cells with either 1 μM LPA or 100 nM S1P for time
points between one and sixty minutes. LPA and S1P each
stimulated p44/42 ERK phosphorylation relative to total
p44/42 ERK protein, with peak phosphorylation occur-
ring after 5 minutes of stimulation, followed by a later
sustained lower level of phosphorylation at 30–60 min-
utes (Figure 6). The latter peak was consistently observed
in both LPA and S1P treated cells, but did not meet statis-
tical criteria for significance in LPA treated cells.
LPA and S1P induce reversible morphological changes in 
hES-NEP cells
LPA and S1P mediate morphological changes reflecting
cytoskeletal rearrangements in multiple neuronal cell
types. We determined the effect of LPA and S1P on hES-
NEP cell morphology using continuous live cell micros-
copy. hES-NEP cells were plated and maintained in an
environmentally controlled slide incubator system that
allows continuous video surveillance of live cells under
controlled temperature and atmospheric conditions. After
treatment with 1 μM LPA (Figure 7A) or 100 nM S1P (Fig-
ure 7B), hES-NEP cells became aggregated and rounded,
retracting cellular extensions. This morphological change
was transient, reaching a peak at approximately 5 hours
after treatment and returning to baseline 18 hours after
treatment (Video of the complete experiment available in:
Additional files 1 and 2). Addition of vehicle caused no
morphological changes under these conditions (data not
shown). In contrast to the effects on the proliferative
response, overnight pre-treatment of the cells with Ptx,
AG1478, or U0126 did not block the ability of LPA (Fig-
ure 8A) or S1P (Figure 9) to induce morphological
changes, while pre-treatment with Y27632, the inhibitor
of p160ROCK, completely prevented cellular aggregation
and rounding induced by either lysophospholipid. These
data suggest that morphological changes induced by LPA
and S1P are mediated by a pathway that does not include
Gi/o proteins, EGF receptors, or MEK, but does require the
Rho effector p160 ROCK. Notably, Ptx treatment alone
caused some cellular aggregation; however, treatment
with either LPA or S1P induced further cell rounding. Fur-
ther, cells pre-treated with Y27632 had longer, thinner
membrane extensions than cells pre-treated with vehicle,
consistent with previous observations by Darenfed et al.
[38].
Discussion
Lysophospholipids are hypothesized to be critical regula-
tors of neuronal differentiation, proliferation, and migra-
tion during development and following injury. While
rodent neural progenitor cells and human transformed
cell lines have been used to establish these roles and inves-
tigate the pathways responsible, the effects of lysophos-
pholipids in human neural progenitor cells has not been
established until now. This study establishes our recently
characterized human embryonic neural epithelial progen-
itor cell line as a valid model system to define the role of
LPA and S1P in neural progenitors during human neural
development, differentiation, and wound healing.
Our results demonstrate that hES-NEP cells express func-
tional LPA and S1P receptors coupled to Gi/o mediated
inhibition of adenylyl cyclase and to a pertussis toxin-
insensitive PLC pathway, likely mediated by Gq. hES-NEP
cells do not express functional Gs coupled receptors for
either LPA or S1P. Like the cAMP inhibitory response, the
proliferative response was also completely inhibited by
Pertussis toxin (Ptx) and is therefore also mediated by Gi/
o coupled receptor subtypes. In contrast, the morphologi-
cal response was not inhibited by Ptx, and so is not medi-
ated by Gi/o coupled receptors. Our data suggest that LPA
and S1P morphological responses may be mediated by
G12 coupled GPCRs, consistent with the observed Rho-
dependency, although we cannot rule out a Gq-mediated
mechanism. All LPA and S1P receptors except LPA3 and
S1P4 were detected in hES-NEP cells. Studies including
additional pharmacologically selective drugs are required
to determine the molecular identity of the receptors medi-
ating the observed responses in hES-NEP cells.
Both LPA and S1P stimulate proliferation of many cell
types. Studies in multiple cell lines [16-18,39,40] suggest
that LPA receptors coupled to Gi/o stimulate cell growth
via EGF receptor transactivation and subsequent MAP
kinase activation, which directly leads to cell prolifera-
tion. While we observed a strong effect of lysophospholi-
pids on cell growth, our data do not distinguish between
effects on proliferation versus survival pathways. Future
work should directly address the effect of LPA and S1P on
apoptosis in these cells. Indeed, LPA does function as a
survival factor in many cancer cell types via activation of
the PI3 Kinase pathway. Nonetheless, our data are consist-
ent with the proliferative EGF receptor transactivation
mechanism described above. The growth responses to
LPA and S1P in these cells were completely inhibited by
Ptx and inhibitors of EGF receptors and ERK Map kinases,
but not by inhibitors of p160 ROCK. Notably, the basal
growth of hES-NEP cells was also inhibited by EGFR and
MAP kinase inhibitors but not p160 ROCK inhibitor, sug-
gesting that basal growth is mediated by a similar path-
way, although not necessarily initiated by LPA or S1P.BMC Neuroscience 2008, 9:118 http://www.biomedcentral.com/1471-2202/9/118
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LPA and S1P induce ERK phosphorylation in hES-NEP cells Figure 6
LPA and S1P induce ERK phosphorylation in hES-NEP cells. hES-NEP cells were treated with 1 μM LPA (A) or 100 
nM S1P (B) for the indicated amounts of time and then assayed for phosphorylated p44/42 ERK and total p44/42 ERK as 
described in Materials and Methods. In each case, results are shown as a Western blot image of a representative experiment 
and a densitometry graph of combined data from two independent experiments analyzed using an unpaired 2-tailed t-test *: p 
< 0.05; **: p < 0.01; ***: p < 0.001.BMC Neuroscience 2008, 9:118 http://www.biomedcentral.com/1471-2202/9/118
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LPA and S1P induce reversible morphology changes in hES-NEP cells Figure 7
LPA and S1P induce reversible morphology changes in hES-NEP cells. hES-NEP cells were incubated with (A) 1 μM 
LPA or (B) 100 nM S1P for 18 hours and subjected to continuous video microscopy. Still images of cell morphology changes 
were recorded as described in Materials and Methods at select time points. Data images are consistent with three independent 
experiments.BMC Neuroscience 2008, 9:118 http://www.biomedcentral.com/1471-2202/9/118
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Morphology changes induced by LPA are blocked the p160ROCK inhibitor Y27632 Figure 8
Morphology changes induced by LPA are blocked the p160ROCK inhibitor Y27632. hES-NEP cells were incubated 
with vehicle, 100 ng/mL Ptx, 2.5 μM AG1478, 10 μM U0126, or 10 μM Y27632 for 18 hours and then treated with 1 μM LPA 
for 18 hours. Images of cell morphology were captured  after treatment with each inhibitor but before addition of LPA (t =  0), 
after five hours of LPA treatment (t = 5) and after 18 hours of LPA treatment (t = 18). Data images are consistent with three  
independent experiments.BMC Neuroscience 2008, 9:118 http://www.biomedcentral.com/1471-2202/9/118
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Morphology changes induced by S1P are blocked the p160ROCK inhibitor Y27632 Figure 9
Morphology changes induced by S1P are blocked the p160ROCK inhibitor Y27632. hES-NEP cells were incubated 
with vehicle, 100 ng/mL Ptx, 2.5 μM AG1478, 10 μM U0126, or 10 μM Y27632 for 18 hours and then treated  with 100 nM S1P 
for 18 hours. Images of cell morphology were captured after treatment with each inhibitor but before addition of S1P (t = 0), 
after five hours of S1P treatment (t = 5) and after 18 hours of S1P treatment (t = 18). Data images are consistent with three 
independent experiments.BMC Neuroscience 2008, 9:118 http://www.biomedcentral.com/1471-2202/9/118
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This also suggests a basal level of ERK MAP kinase activity.
Although the data shown in Figure 6 do not show basal
ERK phosphorylation due to the short exposure times
required to avoid saturation of peak bands for quantifica-
tion, in longer exposures basal ERK phosphorylation was
apparent (data not shown).
The proliferative effect of LPA has been directly demon-
strated in rat embryonic neural stem cells [19]. Cui et al.
report a bell-shaped LPA dose response relationship in
proliferation assays in which LPA increased thymidine
incorporation at concentrations between 10 nanomolar
and 1 micromolar, but inhibited proliferation at higher
concentrations. This biphasic effect of LPA on prolifera-
tion is consistent with both our observation that LPA
stimulates hES-NEP cell growth between 1 nM and 100
nM, and a recent report in which 10 micromolar LPA did
not stimulate proliferation in human neurospheres [25].
Similarly, LPA stimulated production of inositol phos-
phates reached a maximal level at 1 μM and a reduced
activation at higher concentrations.
LPA and S1P effects on morphology of either neurons or
neural progenitors are mediated by effects on the actin
cytoskeleton and/or microtubules, and effects are typi-
cally, but not always, dependent on the small GTPase pro-
tein Rho. Rho is known to regulate axonal growth,
neuronal differentiation, and neuronal survival, primarily
through its well-characterized neuronal effector p160
ROCK (Review:[41]). Rho activation occurs primarily via
activation of Rho exchange factors by G proteins of the
G12 subfamily, and leads to activation of p160 ROCK
which mediates morphological changes by altering
cytoskeletal structure. Specifically, p160 ROCK increases
actin contractility and stress fiber formation via myosin-II
regulatory light chain (MLC) [41] and decreases actin
depolymerization via LIM kinases to regulate growth cone
collapse [24]. Alternately, Gi/o pathways can also alter the
cytoskeleton through activation of Glycogen synthase
kinase-3 (GSK-3) [42] or Rac, which promotes cell spread-
ing [43,44].
The effect of LPA on neural cell morphology varies with
cell type and distinct morphology changes occur over dif-
ferent time scales. Typically, in neurons or neuronal cell
lines that have neurites or growth cones, these retract and
cells round in response to LPA within minutes. In NIE-
115 and NG108-15 cells, and B103 cells expressing either
LPA1 or LPA4, LPA causes a rapid, transient rounding
which initiates at 5 minutes following LPA addition, and
cells recover their flattened morphology after 20 minutes,
even in the continued presence of LPA [21,44]. Alter-
nately, in rat hippocampal NP cells both LPA and S1P
cause transient aggregation with a maximal response at 3
hours and a return to baseline at 18 hours [20,44]. Simi-
larly, in B103 cells expressing exogenous LPA4, but not
LPA1, LPA stimulated a slow aggregation that peaked at
three hours [44]. Like the rapid cell rounding, the slow
cell aggregation response is dependent on the Rho effector
p160 ROCK, as was the slow cell aggregation observed in
this report. In contrast, the known activation time course
of p160 Rho kinase is on a scale of minutes, and Rho acti-
vation occurs even faster. Thus, even though this response
is dependent on Rho/Rho kinase activation, these are not
the rate limiting factors in the response. In our experi-
ments, LPA or S1P were added to the media and not
washed out throughout the experiment. The long recovery
time of shape changes may reflect time course of LPA sta-
bility in the media. Consistent with this explanation,
when media was changed to remove S1P one hour after
addition to cells, morphology changes immediately began
to reverse.
Our data clearly implicate Rho-mediated activation of
ROCK in mediating LPA and S1P stimulated rounding
and aggregation in hES-NEP cells. Inhibition of p160
ROCK completely blocked LPA and S1P stimulated
effects, while both phospholipids could still mediate cell
aggregation and rounding following inactivation of EGFR,
or ERK. Although LPA and S1P still clearly altered cell
morphology following treatment with Ptx, Ptx treatment
itself induced modest cell aggregation. This effect of Ptx
may reflect inhibition of basal Gi/o mediated effects on
GSK-3 or Rac as described above.
While the current study describes LPA and S1P effects on
proliferation and morphological changes, hES-NEPs are
also a promising model cell system in which to study LPA
and S1P effects in multiple processes of neural develop-
ment. There is growing evidence that S1P and LPA regu-
late neuronal differentiation; however, data from various
models report contradictory effects [11,19,20,25,26]. For
example, LPA is reported to increase neuronal differentia-
tion of rat neural progenitors (NP) [19] and mouse neu-
rosphere cultures [11], while more recently LPA was
shown to inhibit neuronal differentiation of human ES
cell-derived neurosphere cultures [25]. These contradic-
tions may reflect bona fide differences in LPA signaling
pathways in rodent versus human neural differentiation,
or they may be a result of mixed cell populations and the
various sources and developmental stages from which the
neural stem cells were isolated. For example, significant
differences in expression of FGF, wnt and LIF pathway
genes are observed between human neural stem cells
derived from hES cells and fetal neural stem cells [45].
Given these potential differences between neural stem
cells from different cell sources, homogeneous multi-
potent human ES cell-derived neuroepithelial (hES-NEP)
cells may be a superior model system in which to eluci-
date the roles of LPA and S1P cell signaling pathways inBMC Neuroscience 2008, 9:118 http://www.biomedcentral.com/1471-2202/9/118
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neural progenitor cells. Future studies of LPA and S1P
effects on differentiation in the homogenous hES-NEP
cell system will serve to clarify the effect of lysophosphol-
ipids on human neural differentiation.
Conclusion
We have defined LPA and S1P signaling pathways in hES-
NEP cells that promote cellular growth and morphologi-
cal changes by distinct mechanisms. This cell system is
superior to rodent and transformed cell systems in which
LPA and S1P effects have been defined by virtue of its
human origin, multi-potent status, and non-transformed
state. Further, as a stable, homogeneous, adherent, renew-
able cell line, hES-NEP cells are a convenient model sys-
tem for future studies defining the functional role of
lysophospholipids in proliferation, differentiation, and
migration in the developmentally important human neu-
ral progenitor cell type.
Methods
Materials
Carbachol, epinephrine, quinpirole, clonidine, bromoc-
riptine, dopamine, and U0126 were purchased from
Sigma-Aldrich (St. Louis, MO). Y27632 and AG1478 were
purchased from Tocris Bioscience (Ellisville, Missouri).
Pertussis toxin was purchased from List Biological Labora-
tories (Campbell, CA) and FR180204 from EMD Bio-
sciences (La Jolla, CA). Oleoyl (18:1) LPA and D-erythro-
sphingosine-1-phosphate were from Avanti Polar Lipids
(Alabaster, AL).
Cell Culture
Commercially available stocks of hES-NEP cells [available
as ENStem-A™ (Millipore, Temecula, CA)] were used.
These cells were derived from WA09 human ES cells and
maintained as described previously[1]. Briefly, cells were
grown on poly-ornithine (20 μg/mL)/laminin (5 μg/mL)
(Sigma-Aldrich St. Louis, MO) coated plates in ENStem-
A™ Neural Expansion Medium with 2 mM L-Glutamine
and 20 ng/mL b-FGF (all from Millipore, Temecula, CA).
Cells were passaged approximately every 48 hours and
split 1:2 following manual dissociation by trituration.
WA09 (WiCel) were cultured in Dulbecco's minimal
essential medium/Ham's F12 medium (DMEM/F12), 2
mM  L-glutamine, 0.1 mM  minimal essential medium
(MEM) nonessential amino acids, 50 U/ml penicillin, 50
μg/ml streptomycin (all from Invitrogen), 4 ng/ml basic
fibroblast growth factor (bFGF; R&D Systems, Minneapo-
lis, MN) and 20% KSR (Invitrogen). Cells were cultured
on mitomycin-C (Sigma Chemical Co., St. Louis, MO)
mitotically inactivated murine embryonic fibroblasts,
manually dissociated, and passaged to new feeder layers
every 4–5 days [46].
Real Time Reverse Transcriptase PCR
RNA was extracted using Qiashredder and RNeasy kits
(Qiagen, Valencia, CA) according to the manufacturer's
instructions. The RNA quality and quantity was verified
using a RNA 600 Nano Assay and an Agilent 2100 Bioan-
alyzer (Agilent Technologies, Santa Clara, CA). Total RNA
was reverse-transcribed using the cDNA Archive Kit
(Applied Biosystems Inc., Foster City, CA) according to
manufacturer's protocols. Quantitative RT-PCR (Taqman)
assays were chosen for the transcripts from a pre-validated
library of human specific QPCR assays, and incorporated
into a 384-well Micro-Fluidics Cards. Relative quantifica-
tion was carried out on the ABI PRISM 7900 Sequence
Detection System (Applied Biosystems Inc., Foster City,
CA). Expression data for each LPA or S1P receptor was first
normalized against endogenous 18S ribosomal RNA
within each cDNA, and then the relative expression in
hES-NEP was compared to hES cells using the ΔΔCT
method of quantification in SDS software (Applied BIo-
systems Inc., Foster City, CA). Relative fold changes were
determined as RQ values for positive changes and -1/RQ
values for negative fold changes. ANOVA statistical analy-
sis was performed using Tukey post-hoc analysis.
Inositol Phosphate Assay
Production of Inositol Phosphates (IP) was quantified
using established protocols [47]. Briefly: To measure IP
production by PLC activation, hES-NEP cells were plated
in 24-well dishes at ~80% confluency. Cells were labeled
with 1 μCi/well [3H] myo-inositol (American Radiola-
beled Chemicals, St. Louis, MO) for 18 hours to label the
cellular pool of phosphatidyl inositol. The cells were
treated with Oleoyl (18:1) LPA (Avanti Polar Lipids, Ala-
baster, AL) or D-erythro-sphingosine-1-phosphate
(Avanti Polar Lipids, Alabaster, AL) in the presence of 10
mM lithium chloride to inhibit degradation of inositol
phosphates for 30 minutes at 37°C. Cells were then lysed
in cold formic acid and neutralized with ammonium
hydroxide, and the lysates were then loaded onto col-
umns of AG 1-X8 anion exchange resin (Biorad, Hercules,
California). The columns were washed with water and
dilute ammonium formate to remove unhydrolyzed lip-
ids. The [3H] IPs were then eluted with 1.2 M ammonium
formate/0.1 M formic acid, and added to scintillation
cocktail for counting. In some experiments, cells were
treated with 100 ng/mL pertussis toxin (Ptx) for 18 hours
prior to IP assay.
cAMP Assay
We used a modified version established protocols [48].
hES-NEP cells were plated in 12-well dishes and labeled
with 0.6 μCi [3H]-adenine (Perkin Elmer, Waltham, MA)
for three hours in the presence or absence of 200 ng/mL
Ptx. Assay buffer containing 1 mM isobutylmethylxan-
thine (IBMX), 50 μM forskolin, and varying concentra-BMC Neuroscience 2008, 9:118 http://www.biomedcentral.com/1471-2202/9/118
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tions of LPA was added to the cells for 20 minutes at
37°C. Reactions were terminated by aspiration followed
by the addition of stop solution containing 1.3 mM cAMP
and 2% sodium dodecyl sulfate. [14C]-cAMP stock was
added to each well to control for recovery of cAMP, fol-
lowed by perchloric acid to lyse cells. Lysates were neutral-
ized with KOH and cAMP was isolated using sequential
column chromatography over Dowex AG-50-W4 cationic
exchange resin (Bio-Rad, Hercules, CA) followed by neu-
tral alumina columns. The resulting eluate was subjected
to scintillation counting after the addition of scintillation
cocktail.
Cellular Growth
hES-NEP cells were plated in 24-well plates at 50,000 cells
per well and grown to reach 50% confluency (approxi-
mately 100,000 cells/well). In some experiments, cells
were pre-treated with the indicated reagents for 18 hours,
triturated to remove them from the plate, and counted
using a hemacytometer to determine the number of cells
per well. Cells were then treated with LPA, S1P, or vehicle
for the indicated amount of time and counted again.
Trypan blue exclusion was used to determine cell viability
following drug treatment (0.4% (wt/vol) solution of
Trypan Blue (Invitrogen, Carlsbad, CA)). Statistical signif-
icance of changes in growth was determined using an
unpaired, two-tailed T-test.
p44/42 ERK MAP Kinase Phosphorylation
hES-NEP cells were plated in 24-well plates. Prior to the
assay, cells were washed one time with ENStem-A™ Neural
Expansion Media and allowed to incubate in 250 μL
media for 15 minutes at 37°C. LPA or S1P was then
applied to the cells for the indicated period of time. The
reaction was terminated by aspirating the media and add-
ing 100 μL protein sample buffer. Cells were harvested
and lysed in protein sample buffer, separated by SDS-
PAGE, transferred to nitrocellulose membranes, and
immunoblotted using a primary antibody targeted against
phospho-ERK or total ERK (Cell Signaling Technology,
Danvers, MA) and peroxidase-conjugated secondary anti-
bodies (Bethyl Laboratories, Montgomery, TX). Bands
were then visualized using SuperSignal Chemilumines-
cent substrate (Pierce, Rockford, IL). Densitometry analy-
sis was performed using Total Lab 1D Gel Analysis
software. Background bands were not subtracted out and
all lanes and bandwidths were of equal size. Densitometry
results for phospho-ERK were normalized to total ERK to
control for loading, and then normalized to maximal ERK
phosphorylation to compare between experiments. Statis-
tical significance of increases in ERK phosphorylation
over basal levels was determined using an unpaired, two-
tailed T-test.
Cell Morphology Studies
Continuous video microscopy of hES-NEP cells was per-
formed using the WaferGen Smart Slide System (Wafer-
Gen, Incorporated, Freemont, CA). hES-NEP cells were
plated on a WaferGen Smart Slide 100 and maintained at
37°C, with the lid at 39°C to prevent condensation. CO2
was maintained at 5% over the course of the experiment,
and negative flow was maintained through systemic purg-
ing every two minutes. Images were obtained using a
Nikon Eclipse TE2000-S microscope, and captured every
two minutes using a Retiga 2000R Fast 1394 camera
(QImaging, Canada). Data were processed using Image
Pro Plus5.1 version 5.1.0.20 (Media Cybernetics, Inc.,
Bethesda, MD).
To study the effects of pharmacological inhibitors on LPA
and S1P stimulated changes in morphology, hES-NEP
cells were plated in 6-well plates. Three areas with approx-
imately equal cell densities were identified in each well
and an image of each of these areas was captured with a
Nikon AZ100 microscope mounted with a Nikon Digital
Sight DS-QiMc camera set at 16× magnification. Cells
were pre-treated with the indicated compounds for 18
hours. LPA or S1P was then applied for an additional 18
hours. Images of the cells were captured in triplicate after
pre-treatment, approximately 5 hours after application of
LPA or S1P, and then again 13 hours later.
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